

Pharmacy Policy

Tavalisse

Policy Number: 9.136

Version Number: 2.0

Version Effective Date: 1/1/2022

Product Applicability All Plan+ Products

Well Sense Health Plan

New Hampshire Medicaid

Boston Medical Center HealthNet Plan

MassHealth- MCO

MassHealth- ACO

Qualified Health Plans/ConnectorCare/Employer Choice Direct

Senior Care Options

Note: Disclaimer and audit information is located at the end of this document.

Prior Authorization Policy

Products Affected:

- Tavalisse (fostamatinib)

The Plan may authorize coverage of the above products for members meeting the following criteria:

Covered Use	All FDA approved and medically accepted indications unless otherwise excluded
Exclusion Criteria	None
Required Medical Information	<ol style="list-style-type: none"> 1. Diagnosis of chronic ITP, and platelet count is less than 30,000/microL consistently for 3 months (lab documentation included); AND 2. An inadequate response or intolerance to a trial of two of the following: <ol style="list-style-type: none"> a. Corticosteroids b. Immune globulin

* Plan refers to Boston Medical Center Health Plan, Inc. and its affiliates and subsidiaries offering health coverage plans to enrolled members. The Plan operates in Massachusetts under the trade name Boston Medical Center HealthNet Plan and in other states under the trade name Well Sense Health Plan.

	<ul style="list-style-type: none"> c. Rituximab d. Promacta. e. Splenectomy
Age Restrictions	18 years or older
Prescriber Restriction	None
Coverage Duration	Initial : 3 month Reauthorization: 12 months
Other criteria	Reauthorization: Documentation of the following: 1. Platelet levels have improved or stabilized to level greater than or equal to 50,000/mm ³

Applicable Coding:

None

Clinical Background Information and References

1. George, JN. Treatment and prognosis of immune (idiopathic) thrombocytopenia purpura in adults. In UpToDate. Accessed June 2017.
2. George, JN. Immune thrombocytopenia (ITP) in adults: Treatment of chronic refractory disease. In UpToDate. Accessed June 2017.
3. Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions, and outcome criteria in immune thrombocytopenia purpura of adults and children: a report from an international working group. Blood 2009;113(11):2386-2393. Available at: <http://bloodjournal.hematologylibrary.org/content/113/11/2386.full.pdf+html>
4. Crowther MA, et al. The American Society of Hematology 2011 Evidence-Based Practice Guideline For Immune Thrombocytopenia. Blood 2011; 117(16):4190-4207.
5. Schrier, S. Treatment of aplastic anemia in adults. In UpToDate. Topic last updated May 16, 2017. Accessed June 2017.
6. George, J, Arnold, D. Immune thrombocytopenia (ITP) in adults: Second-line and subsequent therapies. UpToDate. Last updated: May 29,2018. Accessed June 18, 2018.
7. Tavalisse (fostamatinib) Prescribing Information. Rigel Pharmaceuticals, Inc. South San Francisco, CA 94080. April 2018.

* Plan refers to Boston Medical Center Health Plan, Inc. and its affiliates and subsidiaries offering health coverage plans to enrolled members. The Plan operates in Massachusetts under the trade name Boston Medical Center HealthNet Plan and in other states under the trade name Well Sense Health Plan.

Original Approval Date	Original Effective Date	Policy Owner	Approved by
12/1/2020	1/1/2021	Pharmacy Services	Pharmacy & Therapeutics (P&T) Committee

Policy Revisions History			
Review Date	Summary of Revisions	Revision Effective Date	Approved by
12/1/2020	9.086 Nplate and Tavalisse Policy policy retired, new policy created: split Nplate and Tavalisse into 2 separate policies	1/1/2021	P&T Committee
8/12/2021	P&T Annual review: No Changes	1/1/2022	P&T Committee

Next Review Date

8/2022

Other Applicable Policies

Reference to Applicable Laws and Regulations, If Any

Disclaimer Information

Medical Policies are the Plan's guidelines for determining the medical necessity of certain services or supplies for purposes of determining coverage. These Policies may also describe when a service or supply is considered experimental or investigational, or cosmetic. In making coverage decisions, the Plan uses these guidelines and other Plan Policies, as well as the Member's benefit document, and when appropriate, coordinates with the Member's health care Providers to consider the individual Member's health care needs.

Plan Policies are developed in accordance with applicable state and federal laws and regulations, and accrediting organization standards (including NCQA). Medical Policies are also developed, as appropriate, with consideration of the medical necessity definitions in various Plan products, review of current literature, consultation with practicing Providers in the Plan's service area who are medical experts in the particular field,

* Plan refers to Boston Medical Center Health Plan, Inc. and its affiliates and subsidiaries offering health coverage plans to enrolled members. The Plan operates in Massachusetts under the trade name Boston Medical Center HealthNet Plan and in other states under the trade name Well Sense Health Plan.

and adherence to FDA and other government agency policies. Applicable state or federal mandates, as well as the Member's benefit document, take precedence over these guidelines. Policies are reviewed and updated on an annual basis, or more frequently as needed. Treating providers are solely responsible for the medical advice and treatment of Members.

The use of this Policy is neither a guarantee of payment nor a final prediction of how a specific claim(s) will be adjudicated. Reimbursement is based on many factors, including member eligibility and benefits on the date of service; medical necessity; utilization management guidelines (when applicable); coordination of benefits; adherence with applicable Plan policies and procedures; clinical coding criteria; claim editing logic; and the applicable Plan – Provider agreement.

^{*} *Plan* refers to Boston Medical Center Health Plan, Inc. and its affiliates and subsidiaries offering health coverage plans to enrolled members. The Plan operates in Massachusetts under the trade name Boston Medical Center HealthNet Plan and in other states under the trade name Well Sense Health Plan.